Ataraxis AI to Present 9 Studies at SABCS 2026
Ataraxis will present nine studies featuring Ataraxis™ Breast data at the 2026 San Antonio Breast Cancer Symposium (SABCS), including several oral presentations, two of them in General Session 1. The research validates Ataraxis AI for prognosis and chemotherapy benefit prediction in the landmark TAILORx and SWOG-8814 trials and in multi-national real-world cohorts, with head-to-head comparisons against genomic assays such as the 21-gene recurrence score. Ataraxis will also present first-ever data on predicting response to neoadjuvant therapy, including results from the PHERGain trials.
Oral Presentations on December 9
General Session GS1-1 (Hall 1, 9:30am CT): External Validation of a Causal Multi-Modal AI Model for Prognosis and Chemotherapy Benefit in Node-Negative HR+/HER2– Breast Cancer Patients: Analysis of TAILORx
- Presenter: Nancy Chan, MD (NYU Langone Health)
General Session GS1-2 (Hall 1, 9:30am CT): Blinded Validation of a Causal Multi-Modal AI Model in Postmenopausal, Node-Positive, HR+ Breast Cancer: Analysis of SWOG-8814
- Presenter: Alastair M. Thompson, MD (Indiana University Simon Comprehensive Cancer Center)
Rapid Fire RF3-3 (Stars at Night 1-2, 4:30pm CT): A Multi-Cohort Comparison of Genomic, Clinical, and AI Models for Recurrence Prediction in Early Breast Cancer
- Presenter: Lajos Pusztai, MD, DPhil (Yale School of Medicine)
Poster Presentations on December 9
Poster Session P1-2-10 (Exhibit Hall, 12:30pm CT): Multi-National External Validation of a Causal Multi-Modal AI Model for Prognosis and Chemotherapy Benefit Prediction in HR+/HER2– Breast Cancer
- Presenter: Francisco J. Esteva, MD, PhD (Northwell Health)
Poster Session P2-4-01 (Exhibit Hall, 5:00pm CT): Multi-Modal AI Incorporating Histology-Inferred Gene Expression Enables Comprehensive Breast Cancer Prognostication Over a 10- Year Horizon
- Presenter: Kevin Kalinsky, MD, MS (Winship Cancer Institute, Emory University)
Poster Session P2-4-02 (Exhibit Hall, 5:00pm CT): Comparison of a Multi-Modal AI Model to the 21-Gene Recurrence Score Assay in an External HR+/HER2– Breast Cancer Cohort
- Presenter: Mariam Haji (Roswell Park Comprehensive Cancer Center)
Oral Presentations on December 10
Poster Spotlight PS8-8 (Hemisfair 3, 7:00am CT): Multi-Modal AI Predicts Neoadjuvant Response and Long-Term Outcomes in HER2+ Early Breast Cancer Treated With Chemotherapy De-Escalation Strategies: Analysis of the PHERGain Trials
- Presenter: Giulia Notini, MD (IRCCS San Raffaele Hospital, Milan / MEDSIR)
Poster Presentations on December 10
Poster Session P3-2-25 (Exhibit Hall, 12:30pm CT): Predicting Neoadjuvant Therapy Response From Breast Cancer Core Biopsies Using Multi-Modal AI
- Presenter: Frederick M. Howard, MD (University of Chicago)
Poster Session P3-11-09 (Exhibit Hall, 12:30pm CT): Artificial Intelligence-Enabled Risk Stratification in Invasive Lobular Breast Cancer
- Presenter: Albert Grinshpun, MD (Shaare Zedek Medical Center, Jerusalem)
Booth
Visit us at Booth #1524 & AI MakerSpace Booth Exhibit Hall 3!
